Skip to main content
RXR modulators to improve the efficacy of immunomodulatory agents in multiple myeloma treatment

RXR modulators to improve the efficacy of immunomodulatory agents in multiple myeloma treatment

Unmet Need Multiple myeloma (MM) is the second most common hematological malignancy in the United States. Although current anti-myeloma therapeutics help patients live with the disease for more than 10 years, MM remains an incurable…

Read More

Small molecule inhibitors of eHSP90 to treat autoimmune diseases

Small molecule inhibitors of eHSP90 to treat autoimmune diseases

Unmet Need It is estimated that autoimmune diseases affect 1 out of every 10 individuals. These debilitating diseases are the result of the immune system inappropriately targeting and attacking the body. The resulting disease is…

Read More

Leukocyte phenotyping methods to provide prognostic information and risk/resilience stratification for surgical procedures and critical illness

Leukocyte phenotyping methods to provide prognostic information and risk/resilience stratification for surgical procedures and critical illness

Unmet Need It is estimated that surgical complications arise in 16.4%, or almost 1 in 6 surgical procedures in the United States. Most complications have an immunological basis related to infection or aberrant adaptation to…

Read More

Method for the in vitro differentiation of human dendritic cells from hematopoietic stem cells for research and immunotherapy development

Method for the in vitro differentiation of human dendritic cells from hematopoietic stem cells for research and immunotherapy development

Unmet Need Dendritic cells (DCs) play a critical role in the adaptive immune response by capturing and presenting antigens to activate cytotoxic T-cells. As such, naturally occurring DCs are thought to have crucial antitumor activity…

Read More

A novel T-cell-based immunotherapy for brain cancer

A novel T-cell-based immunotherapy for brain cancer

Unmet Need Cancer immunotherapy represents a new paradigm in cancer treatment with the goal of harnessing the immune system to selectively attack a patient’s tumor. T-cell-based immunotherapies encompass chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes,…

Read More

Method to overcome treatment resistant cancer by rescuing STING signaling

Method to overcome treatment resistant cancer by rescuing STING signaling

Unmet Need Among types of brain cancer, glioblastoma (GBM) is the most common and the most devastating. Over 8000 patients are diagnosed annually in the United States, accounting for half of all primary malignant brain…

Read More

A tool to facilitate high affinity binding between beta-Arrestin and GPCR

A tool to facilitate high affinity binding between beta-Arrestin and GPCR

Unmet Need Beta-arrestins are a highly conserved family of cytosolic adaptor proteins that contribute to a multitude of physiological functions through a canonical interaction with various G protein-coupled receptors (GPCRs). Through agonist binding to GPCRs,…

Read More

Topical MEK inhibition as a new modality for inflammatory skin diseases and cancers

Topical MEK inhibition as a new modality for inflammatory skin diseases and cancers

Unmet Need Inflammatory skin conditions affect many people, with a wide range of severities. Common skin disorders, such as psoriasis and atopic dermatitis, affect close to 20% of the population. Skin lesions associated with bone…

Read More

A genomics-based method to identify cancer patients that will benefit from immune checkpoint therapy

A genomics-based method to identify cancer patients that will benefit from immune checkpoint therapy

Unmet Need Non-small-cell lung cancer accounts for 82% of all lung cancer diagnoses. Immune checkpoint blockade treatment is an exciting new course of action among advanced stage non-small-cell lung cancer patients. However, only a minority…

Read More

Melanoma treatment method using estrogen modulating small molecules

Melanoma treatment method using estrogen modulating small molecules

Unmet Need Metastatic melanoma, skin cancer that has spread, is an incredibly deadly cancer, with a median survivorship of 6-9 months. For patients with melanoma, a frequently used therapy is immune checkpoint blockade (ICB). These…

Read More

Inhibition of NLRP3 inflammasome to treat bladder inflammation

Inhibition of NLRP3 inflammasome to treat bladder inflammation

Unmet Need Benign prostatic hyperplasia, also known as prostate gland enlargement, commonly results in bladder outlet obstruction, BOO, and affects tens of millions of older men globally. Over 14 million men in the United States…

Read More

CaMKK2 as a target for cancer immunotherapy

CaMKK2 as a target for cancer immunotherapy

Tumor cells have the remarkable ability to block the immune system, and in such a way escape the immune response. This is a major problem that causes cancer development and metastasis. The ability of tumor…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us